On this page you will find our recommendations sorted by BNF chapter.

Appraisal Reports are available to stakeholders on request.

Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net

Title Documents Decision Date

Updated

07/06/2022
Flash Glucose Monitoring Flash Glucose Monitoring NTAG position statement - June 2022 - final for web Recommended for use as per NICE guidance subject to NENC Value Based Commissioning Policy being updated 07/06/2022
Insulin Glargine (Toujeo®) Recommendation Recommended as an option 24/11/2015
Insulin Glargine Biosimilar(Abasaglar®) Recommendation Recommended first line 24/11/2015

Updated

07/06/2022
i-Port Advance® for use in children and adults with diabetes Recommendation Recommended as an option 07/06/2022
OmniPod® CSII system for diabetes Recommendation Recommended as an option 02/06/2015
Semaglutide (oral) for type 2 diabetes Recommendation Recommended as an option for intensification of treatment, if use of GLP1RA is clinically appropriate, and if an oral option is preferred. 01/09/2020
Teriparatide Biosimilar Recommendation Recommend for the treatment of osteoporosis in postmenopausal women as per NICE TA161 08/12/2020
Teriparatide for atypical bisphosphonate induced fractures Recommendation Not recommended 23/02/2021

New

07/06/2022
Top Tips and Recommendations for use of Sodium Glucose Co-transporter 2 inhibitors (SGLT2i) in people with Type 2 Diabetes (T2DM) For Glycaemic Control SGLT2 in T2DM Top Tips NTAG v1 - approved June 2022 Approved by NTAG 07/06/2022